- Adaptive Biotechnologies to Report First Quarter 2024 Financial Results on May 7, 2024
- Adaptive Biotechnologies Provides Strategic Review Update and Announces Preliminary First Quarter 2024 Revenue
- Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
- Adaptive Biotechnologies to Present at the TD Cowen 44th Annual Healthcare Conference
- Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results
- Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2023 Financial Results on February 14, 2024
- Adaptive Biotechnologies to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
- Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts Demonstrating the Actionability of clonoSEQ® MRD Testing in Blood Cancer Patient Care and Drug Development at the 65th ASH Annual Meeting
- Adaptive Biotechnologies Reports Third Quarter 2023 Financial Results and Provides Business Update
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.31 |
---|---|
High | 2.48 |
Low | 2.28 |
Bid | 2.38 |
Offer | 2.39 |
Previous close | 2.34 |
Average volume | 2.49m |
---|---|
Shares outstanding | 145.09m |
Free float | 140.88m |
P/E (TTM) | -- |
Market cap | 338.79m USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 18:31 BST.
More ▼